- Home
- MTAL vs EOLS Comparison
MTAL vs EOLS Comparison
Compare MTAL & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- EOLS
- Stock Information
- Founded
- MTAL 2021
- EOLS 2012
- Country
- MTAL Jersey
- EOLS United States
- Employees
- MTAL N/A
- EOLS N/A
- Industry
- MTAL Blank Checks
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- EOLS Health Care
- Exchange
- MTAL Nasdaq
- EOLS Nasdaq
- Market Cap
- MTAL 830.2M
- EOLS 854.0M
- IPO Year
- MTAL 2021
- EOLS 2018
- Fundamental
- Price
- MTAL $9.33
- EOLS $11.99
- Analyst Decision
- MTAL Buy
- EOLS Strong Buy
- Analyst Count
- MTAL 2
- EOLS 4
- Target Price
- MTAL $14.75
- EOLS $24.67
- AVG Volume (30 Days)
- MTAL 466.5K
- EOLS 731.7K
- Earning Date
- MTAL 01-01-0001
- EOLS 03-04-2025
- Dividend Yield
- MTAL N/A
- EOLS N/A
- EPS Growth
- MTAL N/A
- EOLS N/A
- EPS
- MTAL N/A
- EOLS N/A
- Revenue
- MTAL $340,736,000.00
- EOLS $266,274,000.00
- Revenue This Year
- MTAL $24.36
- EOLS $34.56
- Revenue Next Year
- MTAL $16.52
- EOLS $32.26
- P/E Ratio
- MTAL N/A
- EOLS N/A
- Revenue Growth
- MTAL 114.30
- EOLS 31.76
- 52 Week Low
- MTAL $9.26
- EOLS $9.25
- 52 Week High
- MTAL $15.26
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- MTAL 34.15
- EOLS 34.77
- Support Level
- MTAL $10.15
- EOLS $11.59
- Resistance Level
- MTAL $10.88
- EOLS $13.66
- Average True Range (ATR)
- MTAL 0.43
- EOLS 0.53
- MACD
- MTAL -0.10
- EOLS -0.14
- Stochastic Oscillator
- MTAL 3.79
- EOLS 19.32
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.